Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults

Journal of Clinical Pharmacology

Volumn 54, Issue 6, 2014, Pages 619-629

  Wang, Chenguang ^a,b   Allegaert, Karel ^c   Tibboel, Dick ^b   Danhof, Meindert ^a   Van Der Marel, Caroline D ^d   Mathot, Ron A A ^e   Knibbe, Catherijne A J ^a,f  

^a LEIDEN UNIVERSITY   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

allometry; clearance; paracetamol; pediatric; pharmacokinetics

Indexed keywords

PROPACETAMOL; ANALGESIC AGENT; PARACETAMOL;

ADENOTONSILLECTOMY; ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG CLEARANCE; EXTUBATION; GESTATIONAL AGE; GROUPS BY AGE; HUMAN; INFANT; LOADING DRUG DOSE; NEWBORN; PAIN; PAIN ASSESSMENT; PHARMACOEPIDEMIOLOGY; PLASMA CONCENTRATION-TIME CURVE; POSTOPERATIVE ANALGESIA; PREMATURITY; REPEATED DRUG DOSE; SIMULATION; SINGLE DRUG DOSE; AGING; BIOLOGICAL MODEL; CLINICAL TRIAL; MALE; METABOLISM; PRESCHOOL CHILD; YOUNG ADULT;

ACETAMINOPHEN; ADULT; AGING; ANALGESICS, NON-NARCOTIC; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; MODELS, BIOLOGICAL; YOUNG ADULT;

EID: 84899849723     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.259     Document Type: Article

References (36)

1. Oscier C, Bosley N, Milner Q., Paracetamol-a review of three routes of administration. Update Anaesth. 2007; 23: 112-114.
2. Palmer GM, Chen SP, Smith KR, Hardikar W., Introduction and audit of intravenous paracetamol at a tertiary paediatric teaching hospital. Anaesth Intensive Care. 2007; 35 (5): 702-706.
3. Jahr JS, Lee VK., Intravenous acetaminophen. Anesthesiol Clin. 2010; 28 (4): 619-645.
4. Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D., Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011; 128 (6): e1618-e1621.
5. Yurttutan S, Oncel MY, Arayici S, et al. A different first-choice drug in the medical management of patent ductus arteriosus: oral paracetamol. J Matern Fetal Neonatal Med. 2013; 26 (8): 825-827.
6. Allegaert K, Anderson B, Simons S, van Overmeire B., Paracetamol to induce ductus arteriosus closure: is it valid ? Arch Dis Child. 2013; 98 (6): 462-466.
7. Anderson BJ, Woollard GA, Holford NH., A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol. 2000; 50 (2): 125-134.
8. Anderson BJ, van Lingen RA, Hansen TG, Lin YC, Holford NH., Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology. 2002; 96 (6): 1336-1345.
9. Allegaert K, Palmer GM, Anderson BJ., The pharmacokinetics of intravenous paracetamol in neonates: size matters most. Arch Dis Child. 2011; 96 (6): 575-580.
10. Anderson BJ, Pons G, Autret-Leca E, Allegaert K, Boccard E., Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Pediatr Anaesth. 2005; 15 (4): 282-292.
11. Zuppa AF, Hammer GB, Barrett JS, et al. Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. J Pediatr Pharmacol Ther. 2011; 16 (4): 246-261.
12. Mohammed BS, Engelhardt T, Cameron GA, et al. Population pharmacokinetics of single-dose intravenous paracetamol in children. Br J Anaesth. 2012; 108 (5): 823-829.
13. Bonate PL., The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharm Res. 1999; 16 (5): 709-717.
14. Khandelwal A, Hooker AC, Karlsson MO., Influence of correlated covariates on predictive performance for different models. PAGE 20 (2011) Abstr 2220; 2011.
15. Allegaert K, Van der Marel CD, Debeer A, et al. Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. Arch Dis Child Fetal Neonatal Ed. 2004; 89 (1): F25-F28.
16. Allegaert K, Anderson BJ, Naulaers G, et al. Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. Eur J Clin Pharmacol. 2004; 60 (3): 191-197.
17. Prins SA, Van Dijk M, Van Leeuwen P, et al. Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. Pediatr Anaesth. 2008; 18 (7): 582-592.
18. Depre M, van Hecken A, Verbesselt R, Tjandra-Maga TB, Gerin M, de Schepper PJ., Tolerance and pharmacokinetics of propacetamol, a paracetamol formulation for intravenous use. Fundam Clin Pharmacol. 1992; 6 (6): 259-262.
19. Gregoire N, Hovsepian L, Gualano V, Evene E, Dufour G, Gendron A., Safety and pharmacokinetics of paracetamol following intravenous administration of 5 g during the first 24 h with a 2-g starting dose. Clin Pharmacol Ther. 2007; 81 (3): 401-405.
20. van der Marel CD, van Lingen RA, Pluim MA, et al. Analgesic efficacy of rectal versus oral acetaminophen in children after major craniofacial surgery. Clin Pharmacol Ther. 2001; 70 (1): 82-90.
21. van der Marel CD., Paracetamol, Widely used Hardly understood. Rotterdam: Erasmus University Medical Center; 2003.
22. Wang C, Peeters MY, Allegaert K, et al. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res. 2012; 29 (6): 1570-1581.
23. Wang C, Sadhasivam S, Krekels EH, et al. Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. Clin Drug Invest. 2013; 33 (7): 523-534.
24. Bartelink IH, Boelens JJ, Bredius RG, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012; 51 (5): 331-345.
25. Ince I, de Wildt SN, Wang C, et al. A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults. Clin Pharmacokinet. 2013; 52 (7): 555-565.
26. Allegaert K, Naulaers G, Vanhaesebrouck S, Anderson BJ., The paracetamol concentration-effect relation in neonates. Paediatr Anaesth. 2013; 23 (1): 45-50.
27. Keizer RJ, Karlsson MO, Hooker A., Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT: Pharmacomet Syst Pharmacol. 2013; 2: e50.
28. Karlsson MO, Jonsson EN, Wiltse CG, Wade JR., Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J pharmacokinet biopharm. 1998; 26 (2): 207-246.
29. Krekels EH, van Hasselt JG, Tibboel D, Danhof M, Knibbe CA., Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res. 2011; 28 (4): 797-811.
30. Karlsson MO, Savic RM., Diagnosing model diagnostics. Clin Pharmacol Ther. 2007; 82 (1): 17-20.
31. Brendel K, Comets E, Laffont C, Laveille C, Mentre F., Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006; 23 (9): 2036-2049.
32. Paracetamol NKFK., (Perfalgan) Dutch Childrens Formularium. 2013; http://www.kinderformularium.nl/search/stof.php?id=82
33. Mandema JW, Verotta D, Sheiner LB., Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992; 20 (5): 511-528.
34. Krekels EHJ, Neely M, Panoilia E, et al. From pediatric covariate model to semiphysiological function for Maturation: Part I-extrapolation of a covariate model from morphine to zidovudine. CPT: Pharmacomet Syst Pharmacol. 2012; 1: e9.
35. Krekels EHJ, Johnson TN, den Hoedt SM, et al. From pediatric covariate model to semiphysiological function for maturation: Part II-sensitivity to physiological and physicochemical properties. CPT: Pharmacomet Syst Pharmacol. 2012; 1: e10.
36. Palmer GM, Atkins M, Anderson BJ, et al. I.V. acetaminophen pharmacokinetics in neonates after multiple doses. Br J Anaesth. 2008; 101 (4): 523-530.